Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600841 | 0.80 | BRD4 (0.36) | LPLLIPGEGFR | |
| SCHEMBL29525463 | 0.73 | MMP12 (0.45) | LPLLIPGEGFRMAPT | |
| SCHEMBL3306133 | 0.73 | LPL (0.39) | LPLLIPGEGFRROCK1 | |
| SCHEMBL874992 | 0.73 | MMP12 (0.45) | LPLLIPGEGFRMAPT | |
| SCHEMBL3261065 | 0.72 | EGFR (0.34) | LPLLIPGEGFRROCK1 | |
| SCHEMBL6691092 | 0.71 | LPL (0.50) | LPLLIPGROCK1MEN1KMT2A | |
| SCHEMBL25213668 | 0.71 | LPL (0.37) | LPLLIPGEGFRROCK1 | |
| SCHEMBL16728595 | 0.71 | LPL (0.37) | LPLLIPGEGFRROCK1 | |
| SCHEMBL30005887 | 0.71 | LPL (0.37) | LPLLIPGEGFRROCK1 | |
| SCHEMBL25292477 | 0.71 | LPL (0.37) | LPLLIPGEGFRROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| EP-3645536-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | LPL 4849/4885LIPG 4868/4885EGFR 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.